Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 03, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Repurchased: 455,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,215.69 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,215,332,972 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 455,000 repurchased shares. Consequently, the total number of shares in issue stands at 5,215,332,972, while the Treasury holding remains at 474,194,158 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,215,332,972) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the Treasury share count (474,194,158) and its percentage of total voting rights (9.09%).
- Note that this filing does not contain operational or financial performance data for the period.